Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
AstraZeneca
Sort By
Newest First
1 / 3
AstraZeneca Canada
COVID-19 Prevention
AstraZeneca to Supply Canada with 100,000 Doses of Evusheld, a Long-Acting Antibody Combination for the Prevention of COVID-19
AstraZeneca Canada
PR-M02-22-21
Feb 23, 2022
AstraZeneca
Clinical Data
New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
AstraZeneca
PR-M06-21-004
Jun 02, 2021
AstraZeneca
Drug Approval
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
AstraZeneca
PR-M05-21-004-1000
May 06, 2021
HALIX
COVID-19 Vaccine
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
HALIX
PR-M11-20-031
Dec 10, 2020
AstraZeneca
COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials
AstraZeneca
PR-M10-20-07
Oct 13, 2020
AstraZeneca
Breakthrough Therapy
Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease
AstraZeneca
PR-M10-20-02
Oct 02, 2020
AstraZeneca
AstraZeneca, Oxford SARS-CoV-2 Vaccine Trials Temporarily Paused
AstraZeneca
PR-M09-20-NI-11
Sep 09, 2020
Catalent
COVID-19 Vaccine
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Catalent
PR-M08-20-NI-41
Aug 26, 2020
AstraZeneca
Clinical Trials
AstraZeneca Initiates Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for COVID-19
AstraZeneca
PR-M08-20-NI-38
Aug 25, 2020
AstraZeneca
Flu Vaccine
AstraZeneca Ships FLUMIST QUADRIVALENT Vaccine in the U.S. for 2020-2021 Flu Season
AstraZeneca
PR-M08-20-NI-25
Aug 14, 2020
AstraZeneca
COVID-19 Vaccine
AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company
AstraZeneca
PR-M08-20-NI-12
Aug 07, 2020
AstraZeneca
Collaboration
AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate
AstraZeneca
PR-M07-20-NI-41
Jul 27, 2020
AstraZeneca
Approval
AstraZeneca's Breztri Aerosphere Approved in the US for the Maintenance Treatment of COPD
AstraZeneca
PR-M07-20-NI-37
Jul 24, 2020
SGS Life Science Services
COVID-19 Vaccine
SGS Signs Analytical Testing Agreement with AstraZeneca for COVID-19 Vaccine Candidate
SGS Life Science Services
PR-M07-20-NI-28
Jul 17, 2020
AstraZeneca
Clinical Results
AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients
AstraZeneca
PR-M07-20-NI-027
Jul 16, 2020
Daiichi-Sankyo
Vaccine Manufacturing
Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Coronavirus Vaccine
Daiichi-Sankyo
PR-M06-20-NI-036-1473
Jun 26, 2020
AstraZeneca
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
AstraZeneca
PR-M06-20-NI-019-1504
Jun 12, 2020
ArcherDX
Partnership
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease
ArcherDX
PR-M06-20-NI-011
Jun 08, 2020
AstraZeneca
Collaboration
AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics
AstraZeneca
PR-M06-20-NI-005
Jun 04, 2020
AstraZeneca
Oncology
AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials
AstraZeneca
PR-M05-20-NI-044
May 29, 2020
1 / 3
